- Home
- ATHE vs RDHL Comparison
ATHE vs RDHL Comparison
Compare ATHE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHE
- RDHL
- Stock Information
- Founded
- ATHE 1997
- RDHL 2009
- Country
- ATHE Australia
- RDHL Israel
- Employees
- ATHE N/A
- RDHL N/A
- Industry
- ATHE Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ATHE Health Care
- RDHL Health Care
- Exchange
- ATHE Nasdaq
- RDHL Nasdaq
- Market Cap
- ATHE 10.1M
- RDHL 8.6M
- IPO Year
- ATHE N/A
- RDHL N/A
- Fundamental
- Price
- ATHE $2.20
- RDHL $6.50
- Analyst Decision
- ATHE Strong Buy
- RDHL
- Analyst Count
- ATHE 2
- RDHL 0
- Target Price
- ATHE $6.00
- RDHL N/A
- AVG Volume (30 Days)
- ATHE 121.1K
- RDHL 21.6K
- Earning Date
- ATHE 02-15-2025
- RDHL 01-03-2025
- Dividend Yield
- ATHE N/A
- RDHL N/A
- EPS Growth
- ATHE N/A
- RDHL N/A
- EPS
- ATHE N/A
- RDHL N/A
- Revenue
- ATHE $2,681,669.00
- RDHL $3,707,000.00
- Revenue This Year
- ATHE N/A
- RDHL $224.90
- Revenue Next Year
- ATHE N/A
- RDHL $82.69
- P/E Ratio
- ATHE N/A
- RDHL N/A
- Revenue Growth
- ATHE 2.63
- RDHL N/A
- 52 Week Low
- ATHE $1.00
- RDHL $6.00
- 52 Week High
- ATHE $3.19
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- ATHE 64.85
- RDHL 38.21
- Support Level
- ATHE $2.04
- RDHL $6.00
- Resistance Level
- ATHE $2.45
- RDHL $7.30
- Average True Range (ATR)
- ATHE 0.23
- RDHL 0.51
- MACD
- ATHE -0.00
- RDHL -0.09
- Stochastic Oscillator
- ATHE 71.15
- RDHL 21.10
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.